Corvus Pharmaceuticals, Inc.
CRVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001626971
No open-market purchases or sales by Corvus Pharmaceuticals, Inc. insiders were filed in the last 90 days; 173 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Corvus Pharmaceuticals, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 47 | 47 | 0 |
| Shares | 17.9M | 27.6M | +9.69M (+54.1%) |
| Value | $31.9M | $50.2M | +$18.4M (+57.6%) |
New holders (7)
Institutions that held Corvus Pharmaceuticals, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Point72 Asset Management, L.P. | 5,964,510 | $10.9M | 0.04% |
| Marshall Wace, LLP | 74,559 | $135.7K | 0.00% |
| Citadel Advisors LLC | 53,010 | $96.5K | 0.00% |
| Cubist Systematic Strategies, LLC | 24,364 | $44.3K | 0.00% |
| Two Sigma Securities, LLC | 11,384 | $20.7K | 0.00% |
| Royal Bank of Canada | 7,238 | $13.0K | 0.00% |
| Bank of America Corp | 392 | $713 | 0.00% |
Sold out (7)
Institutions that held Corvus Pharmaceuticals, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| BVF Inc | 361,406 | $643.3K |
| Virtu Financial LLC | 12,570 | $22.0K |
| Fortem Financial Group, LLC | 11,000 | $19.6K |
| Group One Trading, L.P. | 4,604 | $8.20K |
| Qube Research & Technologies Ltd | 2,378 | $4.23K |
| Wells Fargo & Company | 265 | $472 |
| ICA Group Wealth Management, LLC | 165 | $294 |